Efficacy and tolerability of alirocumab in Austrian clinical practice - results of the non-interventional PEARL-AT study.

<h4>Objective</h4>Proprotein convertase subtilisin/kexin type 9 inhibition can be an effective treatment in patients with primary hypercholesterolemia, particularly in cases with concomitant coronary heart disease, peripheral artery occlusive disease or cerebrovascular occlusive disease for secondar... View More